Hyderabad-based vaccine manufacturer Bharat Biotech said on Saturday that its trials for Covaxin booster dose have shown 'long-term safety with no serious adverse events'.
Bharat Biotech said that 90 percent of the recipients of the booster dose had a "detectable neutralising antibody response" against the wild-type strain, six months after the second dose.